-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Velpatasvir-[d7]
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2172676-02-5.gif)
| Category | HCV Protease |
| CAS | 2172676-02-5 |
| Description | Velpatasvir-[d7] is the labelled analogue of Velpatasvir, which is a selective Hepatitis C virus NS 5 protein inhibitor. |
Product Information
| Synonyms | Velpatasvir-d7; N-[(1R)-2-[(2S,4S)-2-[5-[1,11-dihydro-2-[(2S,5S)-1-[(2S)-2-[(methoxy-d3-carbonyl)amino]-3-methyl-1-oxobutyl-2-d]-5-methyl-2-pyrrolidinyl][2]benzopyrano[4',3':6,7]naphth[1,2-d]imidazol-9-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)-1-pyrrolidinyl]-2-oxo-1-phenylethyl]-carbamic Acid Methyl-d3 Ester |
| IUPAC Name | methyl-d3 ((R)-2-((2S,4S)-2-(5-(2-((2S,5S)-1-(((methoxy-d3)carbonyl)-L-valyl-2-d)-5-methylpyrrolidin-2-yl)-3,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl)-2-oxo-1-phenylethyl)carbamate |
| Molecular Weight | 890.04 |
| Molecular Formula | C49H47D7N8O8 |
| Canonical SMILES | CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC |
| Purity | ≥98% (HPLC) |
| Solubility | Soluble in DMSO (Slightly), Methanol (Slightly) |
| Appearance | Off-white Solid |
| Storage | Store at -20°C |
| Complexity | 1690 |
| Exact Mass | 889.45039793 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| Target | HCV; SARS-CoV |
| XLogP3-AA | 6.2 |
